Zevra Therapeutics
7 Hawkeye Drive
Suite 103
North Liberty
Iowa
52317
United States
Tel: 319-665-2575
Fax: 319-665-2577
Website: http://www.kempharm.com/
Email: info@kempharm.com
240 articles about Zevra Therapeutics
-
KemPharm Reports Second Quarter 2017 Results
8/11/2017
-
KemPharm Announces Preliminary Results From KP415 Pharmacokinetic Single And Multiple Dose Trial
8/10/2017
-
KemPharm Announces Publication Of Study Of Intranasal Abuse Of Hydrocodone Combination Products In Pharmacoepidemiology & Drug Safety
8/8/2017
-
KemPharm To Report Second Quarter 2017 Results
8/1/2017
-
KemPharm Strengthens ADHD Prodrug Pipeline With Development Of KP484, A New, Super-Extended Release ADHD Methylphenidate Product Candidate
6/28/2017
-
KemPharm To Present Clinical Data For KP511, An Opioid Prodrug Candidate, At The International Conference On Opioids
6/9/2017
-
KemPharm Announces Addition To Leadership Team
6/1/2017
-
KemPharm Reports First Quarter 2017 Results
5/11/2017
-
KemPharm To Report First Quarter 2017 Results
5/1/2017
-
Unclear Whether FDA Took Into Account KemPharm's Amendment Data in Rejecting Apadaz Application
6/14/2016
-
KemPharm Crashes After the FDA Votes Against Abuse-Deterrent Labeling for Pain Med
5/6/2016
-
KemPharm To Report First Quarter 2016 Results
5/3/2016
-
KemPharm Files IND For KP511, An Investigational Prodrug Of Hydromorphone
3/7/2016
-
KemPharm Submits NDA For KP201/APAP And Requests Priority Review From The FDA
12/15/2015
-
KemPharm Reports Q3 2015 Results
11/13/2015
-
KemPharm To Report Third Quarter 2015 Results
11/6/2015
-
KemPharm Completes Human Abuse Liability Program For KP201/APAP
10/22/2015
-
KemPharm Enhances U.S. And Global Intellectual Property Estate
10/13/2015
-
KemPharm Reports Positive Data Demonstrating Tamper-Resistant Properties Of KP201/APAP
9/30/2015
-
KemPharm Expands Its Abuse-Deterrent Opioid Pipeline With New Acetaminophen-Free, Immediate Release Hydrocodone And Immediate Release Oxycodone Prodrug Product Candidates
9/24/2015